Catalyst Pharmaceuticals Joins Russell 3000 Index
26 June 2017 - 10:03PM
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical
company focused on developing and commercializing innovative
therapies for people with rare debilitating neuromuscular and
neurological diseases, today announced that the company has been
added to the broad-market Russell 3000® Index at the conclusion of
the Russell indexes annual reconstitution, effective after the US
market opens on June 26, according to a preliminary list of
additions posted June 9.
Annual Russell indexes reconstitution captures
the 4,000 largest US stocks as of the end of May, ranking them by
total market capitalization. Membership in the US all-cap Russell
3000® Index, which remains in place for one year, means automatic
inclusion in the large-cap Russell 1000® Index or small-cap Russell
2000® Index as well as the appropriate growth and value style
indexes. FTSE Russell determines membership for its Russell indexes
primarily by objective, market-capitalization rankings and style
attributes.
"We are pleased that Catalyst Pharmaceuticals
has been added as a member of the Russell 3000®," commented Patrick
McEnany, president and chief executive officer. "This membership
validates our recent strategy and will enhance our visibility in
the investment community."
Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. Approximately $8.4
trillion in assets are benchmarked against Russell’s US indexes.
Russell indexes are part of FTSE Russell, a leading global index
provider.
About FTSE
Russell
FTSE Russell is a leading global index provider
creating and managing a wide range of indexes, data and analytic
solutions to meet client needs across asset classes, style and
strategies. Covering 98% of the investable market, FTSE Russell
indexes offer a true picture of global markets, combined with the
specialist knowledge gained from developing local benchmarks around
the world.
About Catalyst
Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing innovative
therapies for people with rare debilitating neuromuscular and
neurological diseases, including Lambert-Eaton myasthenic syndrome
(LEMS), congenital myasthenic syndromes (CMS), MuSK antibody
positive myasthenia gravis and infantile spasms. Firdapse® has
received Breakthrough Therapy Designation from the U.S. Food and
Drug Administration (FDA) for the treatment of LEMS and Orphan Drug
Designation for LEMS, CMS and myasthenia gravis. Firdapse is the
first and only approved drug in Europe for symptomatic treatment in
adults with LEMS.
Catalyst is also developing CPP-115 to treat
refractory infantile spasms, and possibly refractory Tourette's
Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for
the treatment of infantile spasms by the FDA and has been granted
E.U. Orphan Medicinal Product Designation for the treatment of West
syndrome by the European Commission. In addition, Catalyst is
developing a generic version of Sabril® (vigabatrin).
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2016 and its other
filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on Catalyst's
website, or may be obtained upon request from Catalyst. Catalyst
does not undertake any obligation to update the information
contained herein, which speaks only as of this date.
Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
bkorb@troutgroup.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2024 to May 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From May 2023 to May 2024